
NeurAxis Stock Soars on Groundbreaking FDA Clearance for Pediatric Treatment
May 20, 2025 Nirit Abermann NeurAxis (NRXS) stock surged 82% to $4.13, hitting a high of $6.20, after receiving FDA clearance for IB-Stim to treat pediatric Functional Abdominal Pain and Functional Dyspepsia with nausea, the first such approval. The …